Drugs / CD22-CAR
CD22-CAR
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT04088890 | Sep 2019 → Nov 2024 | diffuse large B-cell lymphoma | Matthew Frank | Completed | No outcome recorded |
| Phase 1 | NCT02315612 | Dec 2014 → Apr 2019 | follicular lymphoma, precursor B-cell acute lymphoblastic leukemia | National Cancer Institute (NCI) | Completed | No outcome recorded |
Evidence & citations 6 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | CD22-CAR | “Autologous T cells transduced with lentiviral vector (CD22.BB.Z) Chimeric Antigen Receptor (CD22 CAR).” NCT04088890 ↗ |
| Known as | CAR22 | “the efficacy of a CD22-directed CAR T-cell therapy (CAR22) in large B-cell lymphoma is unknown” PMID 38996463 ↗ Jul 2024 |
| Known as | CD22.BB.Z | “Autologous T cells transduced with lentiviral vector (CD22.BB.Z) Chimeric Antigen Receptor (CD22 CAR).” NCT04088890 ↗ |
| Known as | M971BBz | “lentiviral vector supernatant containing the anti-CD22 (M971BBz) CAR.” NCT02315612 ↗ |
| Modality | Cell therapy | “anti-CD22 Chimeric Antigen Receptor (CAR) cells” NCT02315612 ↗ |
| Route | Intravenous | “anti-CD22 CAR cells through IV” NCT02315612 ↗ |